Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity

Toxicology and Applied Pharmacology

Volumn 293, Issue , 2016, Pages 44-52

  Pecoraro, Michela ^a   Del Pizzo, Mariagiovanna ^a   Marzocco, Stefania ^a   Sorrentino, Rosalinda ^a   Ciccarelli, Michele ^b   Iaccarino, Guido ^b   Pinto, Aldo ^a   Popolo, Ada ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

Cardiotoxicity; Cytokines; Doxorubicin; Inflammation; Nitric oxide

Indexed keywords

3 NITROTYROSINE; DOXORUBICIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 6; NITRITE; TUMOR NECROSIS FACTOR ALPHA; 3-NITROTYROSINE; ANTINEOPLASTIC ANTIBIOTIC; IL10 PROTEIN, MOUSE; INTERLEUKIN-6, MOUSE; NOS2 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ECHOGRAPHY; GENE OVEREXPRESSION; HEART; HEART FUNCTION; HISTOPATHOLOGY; MOUSE; NONHUMAN; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; DISEASE MODEL; ECHOCARDIOGRAPHY; FEMALE; METABOLISM; PATHOLOGY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTOXICITY; DISEASE MODELS, ANIMAL; DOXORUBICIN; ECHOCARDIOGRAPHY; FEMALE; INTERLEUKIN-10; INTERLEUKIN-6; MICE, INBRED C57BL; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE;

EID: 84954285030     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2016.01.006     Document Type: Article

References (41)

1. Abd El-Aziz T.A., Mohamed R.H., Pasha H.F., Abdel-Aziz H.R. Catechin protects against oxidative stress and inflammatory-mediated cardiotoxicity in adriamycin-treated rats. Clin. Exp. Med. 2012, 12(4):233-240.
2. Adesso S., Popolo A., Bianco G., Sorrentino R., Pinto A., Autore G., Marzocco S. The uremic toxin indoxyl sulphate enhances macrophage response to LPS. PLoS One 2013, 8(9):e76778. Sep 30.
3. Asadullah K., Sterry W., Volk H.D. Interleukin-10 therapy-review of a new approach. Pharmacol. Rev. 2003, 55(2):241-269.
4. Bozkurt B. Activation of cytokines as a mechanism of disease progression in heart failure. Ann. Rheum. Dis. 2000, 59:i90-i93.
5. Cardinale D., Sandri M.T. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog. Cardiovasc. Dis. 2010, 53(2):121-129.
6. Del Regno M., Adesso S., Popolo A., Quaroni A., Autore G., Severino L., Marzocco S. Nivalenol induces oxidative stress and increases deoxynivalenol pro-oxidant effect in intestinal epithelial cells. Toxicol. Appl. Pharmacol. 2015, 285(2):118-127.
7. Di Iorio B., Marzocco S., Micco L.D., Adesso S., Blasio A.D., Autore G., Sirico M.L., Fazeli G., Heidland A. High-tone external muscle stimulation in patients with acute kidney injury (AKI): beneficial effects on NO metabolism, asymmetric dimethylarginine, and endothelin-1. Clin. Nephrol. 2014, 82(5):304-312.
8. Feldman A.M., Combes A., Wagner D., Kadakomi T., Kubota T., Li Y.Y., McTiernan C. The role of tumor necrosis factor in the pathophysiology of heart failure. J. Am. Coll. Cardiol. 2000, 35(3):537-544. Mar 1.
9. Ferrari R., Bachetti T., Confortini R., Opasich C., Febo O., Corti A., Cassani G., Visioli O. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995, 92(6):1479-1486.
10. Freireich E.J. The future of clinical cancer research in the next millennium. Clin. Cancer Res. 1997, 3(12 Pt 2):2563-2570.
11. Gullestad L., Ueland T., Vinge L.E., Finsen A., Yndestad A., Aukrust P. Inflammatory cytokines in heart failure: mediators and markers. Cardiology 2012, 122(1):23-35.
12. Guo R., Wu K., Chen J., Mo L., Hua X., Zheng D., Chen P., Chen G., Xu W., Feng J. Exogenous hydrogen sulfide protects against doxorubicin-induced inflammation and cytotoxicity by inhibiting p38MAPK/NFκB pathway in H9c2 cardiac cells. Cell. Physiol. Biochem. 2013, 32(6):1668-1680.
13. Guo R.M., Xu W.M., Lin J.C., Mo L.Q., Hua X.X., Chen P.X., Wu K., Zheng D.D., Feng J.Q. Activation of the p38 MAPK/NF-κB pathway contributes to doxorubicin-induced inflammation and cytotoxicity in H9c2 cardiac cells. Mol Med Rep. 2013, 8(2):603-608. Aug.
14. Hadi N., Yousif N.G., Al-amran F.G., Huntei N.K., Mohammad B.I., Ali S.J. Vitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory response. BMC Cardiovasc. Disord. 2012, 12:63.
15. Ikegami E., Fukazawa R., Kanbe M., Watanabe M., Abe M., Watanabe M., Kamisago M., Hajikano M., Katsube Y., Ogawa S. Edaravone, a potent free radical scavenger, prevents anthracycline-induced myocardial cell death. Circ. J. 2007, 71(11):1815-1820.
16. Imondi A.R., Della T.P., Mazué G., Sullivan T.M., Robbins T.L., Hagerman L.M., Podestà A., Pinciroli G. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. Cancer Res. 1996, 56(18):4200-4204.
17. Kanda T., Takahashi T. Interleukin-6 and cardiovascular diseases. Jpn. Heart J. 2004, 45(2):183-193.
18. Kinova E., Zlatareva N., Goudev A. Right atrial thrombus from inferior vena cava after acute cardiotoxicity of 5-fluorouracil. Cardiol. J. 2008, 15(3):284-285.
19. Li K., Sung R.Y., Huang W.Z., Yang M., Pong N.H., Lee S.M., Chan W.Y., Zhao H., To M.Y., Fok T.F., Li C.K., Wong Y.O., Ng P.C. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 2006, 113(18):2211-2220.
20. Lim S.C. Interrelation between expression of ADAM 10 and MMP 9 and synthesis of peroxynitrite in doxorubicin induced cardiomyopathy. Biomol. Ther. 2013, 21(15):371-380.
21. MacGowan G.A., Mann D.L., Kormos R.L., Feldman A.M., Murali S. Circulating interleukin-6 in severe heart failure. Am. J. Cardiol. 1997, 79(8):1128-1131.
22. Mercuro G., Cadeddu C., Piras A., Dessì M., Madeddu C., Deidda M., Serpe R., Massa E., Mantovani G. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 2007, 12(9):1124-1133.
23. Octavia Y., Tocchetti C.G., Gabrielson K.L., Janssens S., Crijns H.J., Moens A.L. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J. Mol. Cell. Cardiol. 2012, 52(6):1213-1225.
24. Oliveira M.S., Melo M.B., Carvalho J.L., Melo I.M., Lavor M.S., Gomes D.A., de Goes A.M., Melo M.M. Doxorubicin cardiotoxicity and cardiac function improvement after stem cell therapy diagnosed by strain echocardiography. J Cancer Sci Ther 2013, 5(2):52-57.
25. Pacher P., Liaudet L., Bai P., Mabley J.G., Kaminski P.M., Virág L., Deb A., Szabó E., Ungvári Z., Wolin M.S., Groves J.T., Szabó C. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 2003, 107(6):896-904. Feb 18.
26. Polegato B.F., Minicucci M.F., Azevedo P.S., Carvalho R.F., Chiuso-Minicucci F., Pereira E.J., Paiva S.A.R., Zornoff L.A.M., Okoshi M.P., Matsubara B.B., Matsubara L.S. Acute doxorubicin-induced cardiotoxicity is associated with matrix metalloproteinase-2 alterations in rats. Cell. Physiol. Biochem. 2015, 35:1924-1933.
27. Popolo A., Autore G., Pinto A., Marzocco S. Oxidative stress in patients with cardiovascular disease and chronic renal failure. Free Radic. Res. 2013, 47(5):346-356. May.
28. Riad A., Bien S., Wastermann D., Becher P.M., Loya K., Landmesser U., Kroemer H.K., Schultheiss H.P., Tschpe C. Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice. Cancer Res. 2009, 69:695-699.
29. Robert J. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors. Cardiovasc. Toxicol. 2007, 7:135-139.
30. Salazar-Mendiguchía J., González-Costello J., Roca J., Ariza-Solé A., Manito N., Cequier A. Anthracycline-mediated cardiomyopathy: basic molecular knowledge for the cardiologist. Arch. Cardiol. Mex. 2014, 84(3):218-223.
31. Satoh M., Nakamura M., Akatsu T., Shimoda Y., Segawa I., Hiramori K. C-reactive protein co-expresses with tumor necrosis factor-alpha in the myocardium in human dilated cardiomyopathy. Eur. J. Heart Fail. 2005, 7(5):748-754.
32. Sorriento D., Santulli G., Franco A., Cipolletta E., Napolitano L., Gambardella J., Gomez-Monterrey I., Campiglia P., Trimarco B., Iaccarino G., Ciccarelli M. Integrating GRK2 and NFkappaB in the pathophysiology of cardiac hypertrophy. J. Cardiovasc. Transl. Res. 2015, Jul 30.
33. Tak P.P., Firestein G.S. NF-κB: a key role in inflammatory diseases. J. Clin. Invest. 2001, 107(1):7-11.
34. Takimoto Y., Aoyama T., Tanaka K., Keyamura R., Yui Y., Sasayama S. Augmented expression of neuronal nitric oxide synthase in the atria parasympathetically decreases heart rate during acute myocardial infarction in rats. Circulation 2002, 105(4):490-496.
35. Testa M., Yeh M., Lee P., Fanelli R., Loperfido F., Berman J.W., LeJemtel T.H. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J. Am. Coll. Cardiol. 1996, 28(4):964-971.
36. Tsutamoto T., Wada A., Matsumoto T., Maeda K., Mabuchi N., Hayashi M., Tsutsui T., Ohnishi M., Sawaki M., Fujii M., Matsumoto T., Yamamoto T., Horie H., Sugimoto Y., Kinoshita M. Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 2001, 37(8):2086-2092.
37. Vyas D., Laput G., Vyas A. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. OncoTargets and Therapy 2014, 7:1015-1023.
38. Weinstein D.M., Mihm M.J., Bauer J.A. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J. Pharmacol. Exp. Ther. 2000, 294(1):396-401. Jul.
39. Wong J., Smith L.B., Magun E.A., Engstrom T., Kelley-Howard K., Jandhyala D.M., Thorpe C.M., Magun B.E., Wood L.J. Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin. Cancer Biol. Ther. 2013, 14(1):56-63.
40. Zhu W., Soonpaa M.H., Chen H., Shen W., Payne R.M., Liechty E.A., Caldwell R.L., Shou W., Field L.J. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 2009, 119(1):99-106.
41. Zhu J., Zhang J., Zhang L., Du R., Xiang D., Wu M., Zhang R., Han W. Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity. Biomed. Pharmacother. 2011, 65(7):481-485.